Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) has announced that recently, the company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., have received approval from the National Medical Products Administration for the clinical trial of SHR-9539 injection and HRS-3738 tablets, as indicated in the "Drug Clinical Trial Approval Notice," and will begin the clinical trials soon. SHR-9539 injection is a class 1 therapeutic biological product that activates T cells to target and kill multiple myeloma cells. Currently, there are no similar approved drugs on the market in China. As of now, the accumulated research and development investment for the SHR-9539 injection project is approximately 39.93 million yuan. HRS-3738 tablets are a new generation of potent CRBNE3 ubiquitin ligase modulators, which degrade specific substrates to inhibit the proliferation of hematologic cancer cells. They have the potential advantage of strong substrate degradation ability and overcoming drug resistance. Upon inquiry, there are no similar approved drugs on the market domestically or internationally. As of now, the accumulated research and development investment for the HRS-3738 tablet project is approximately 63.63 million yuan.